Xaluritamig Clinical Trials
6 recruitingDrug
Phase 14Phase 32
Showing 1–6 of 6 trials
Recruiting
Phase 1
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Amgen40 enrolled3 locationsNCT07493512
Recruiting
Phase 3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Amgen750 enrolled134 locationsNCT07213674
Recruiting
Phase 1
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Ewing Sarcoma
Amgen50 enrolled7 locationsNCT07297979
Recruiting
Phase 1
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Prostate Cancer
Amgen40 enrolled9 locationsNCT06613100
Recruiting
Phase 1
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Amgen60 enrolled14 locationsNCT07140900
Recruiting
Phase 3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Metastatic Castration-resistant Prostate Cancer
Amgen675 enrolled164 locationsNCT06691984